Exelixis, Inc. (EXEL) was a big mover last session, as the company saw its shares rise over 11% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up over 16% in the past one-month time frame.
This biotechnology company has seen no estimate revision in the last 30 days. The Zacks Consensus Estimate hasn’t been in trend either. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Exelixis currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Better-ranked stocks in the BioMed industry include Gentium S.p.A (GENT), Genomic Health Inc. (GHDX) and Achillion Pharmaceuticals, Inc. (ACHN). While Gentium and Genomic Health sport a Zacks Rank #1 (Strong Buy), Achillion carries a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
EXELIXIS INC (EXEL): Free Stock Analysis Report
GENTIUM SPA GENTIUM SPA ADS ADSS (GENT): Free Stock Analysis Report
GENOMIC HEALTH INC (GHDX): Free Stock Analysis Report
ACHILLION PHARMACEUTICALS INC (ACHN): Free Stock Analysis Report
Zacks Investment Research
- Finance Trading
- Personal Investing Ideas & Strategies